Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308590 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
A Phase 3 study of Hypercortisolism, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 137
- Enrollment target
- 20
- Study locations
NCT04308590 is a Phase 3 study of Hypercortisolism that has completed, run by Corcept Therapeutics. The registered enrollment target is 137 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT04308590, a Phase 3 study of Hypercortisolism, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 137 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontrolled systolic hypertension (HTN).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Relacorilant
Study Locations (20)
Texas
- Site 20 - Dallas
- Site 03 - El Paso
- Site 05 - Fort Worth
California
- Site 17 - Stanford
- Site 53 - Torrance
New York
- Site 10 - Jamaica
- Site 44 - New York
Ohio
- Site 30 - Cleveland
- Site 21 - Columbus
Alabama
- Site 27 - Birmingham
Georgia
- Site 07 - Atlanta
Indiana
- Site 16 - Indianapolis
Louisiana
- Site 09 - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2024-09-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04308590
The ClinicalTrials.gov registry entry for NCT04308590 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercortisolism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04308590 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, California, New York.
Frequently Asked Questions
What is clinical trial NCT04308590 about?
NCT04308590 is a clinical study titled "A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas". This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontro...
What is the current status of trial NCT04308590?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 137 participants. The study started on 2020-07-27. Estimated completion is 2024-09-19.
What conditions does trial NCT04308590 study?
This clinical trial studies the following conditions: Hypercortisolism.
What interventions are being tested in trial NCT04308590?
The interventions under investigation include: Placebo (OTHER), Relacorilant (DRUG).
Who is sponsoring clinical trial NCT04308590?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04308590 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercortisolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.